Pathogenetic mechanism of microcirculatory disturbance and treatment advances in acute pancreatitis

Hou Fei; Liu RuiXia; Yin ChengHong

doi:10.3969/j.issn.1001-5256.2014.08.033

Issue 8

Aug. 2014

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2014 > 30(8): 815-818

PDF( 1412 KB)

Pathogenetic mechanism of microcirculatory disturbance and treatment advances in acute pancreatitis

DOI: 10.3969/j.issn.1001-5256.2014.08.033

Department of Infection, Beijing Friendship Hospital, Capital Medical University

Research funding:

Received Date: 2014-07-14
Published Date: 2014-08-20

Abstract

Abstract

In recent years, there has been increasing evidence that microcirculatory disturbance, including vasoconstriction, shunting, inadequate perfusion, increased blood viscosity, and coagulation, is closely associated with the pathogenesis of acute pancreatitis (AP) .These processes may be exacerbated by ischaemia- reperfusion injury and the generation of oxygen radicals.The anatomical features of pancreatic microcirculation, the pathophysiological mechanism of pancreatic microcirculation disturbance and related inflammatory mediators, and progress in the treatment of microcirculatory disturbance in AP are reviewed.It is suggested that the pancreatic and systemic microcirculation may play a key role in the development and progression of AP.
- acute pancreatitis,
- microcirculation,
- anatomy,
- pathologic processes,
- chemokines,
- therapeutics,
- review

FullText(HTML)

References(40)

References

[1]SAND J, NORDBACK I.Acute pancreatitis:risk of recurrence and late consequences of the disease[J].Nat Rev Gastroenterol Hepatol, 2009, 6 (8) :470-477.

[2]WHITCOMB DC.Clinical practice.Acute pancreatitis[J].N Engl J Med, 2006, 354 (20) :2142-2150.

[3]YADAV D, LOWENFELS AB.The epidemiology of pancreatitis and pancreatic cancer[J].Gastroenterology, 2013, 144 (6) :1252-1261.

[4]MITCHELL RM, BYRNE MF, BAILLIE J.Pancreatitis[J].Lancet, 2003, 361 (9367) :1447-1455.

[5]PLUSCZYK T, WITZEL B, MENGER MD, et al.ETA and ETB receptor function in pancreatitis-associated microcirculatory failure, inflammation, and parenchymal injury[J].Am J Physiol Gastrointest Liver Physiol, 2003, 285 (1) :g145-g153.

[6]TAKEDA K, MIKAMI Y, FUKUYAMA S, et al.Pancreatic ischemia associated with vasospasm in the early phase of human acute necrotizing pancreatitis[J].Pancreas, 2005, 30 (1) :40-49.

[7]ZHANG XP, LI ZJ, ZHANG J.Inflammatory mediators and microcirculatory disturbance in acute pancreatitis[J].Hepatobiliary Pancreat Dis Int, 2009, 8 (4) :351-357.

[8]KOH YY, JEON WK, CHO YK, et al.The effect of intestinal permeability and endotoxemia on the prognosis of acute pancreatitis[J].Gut Liver, 2012, 6 (4) :505-511.

[9]DABROWSKI A, OSADA J, DABROWSKA MI, et al.Increased expression of the intercellular adhesion molecule-1 (ICAM-1) on peripheral blood neutrophils in acute pancreatitis[J].Adv Med Sci, 2014, 59 (1) :102-107.

[10]ROUDEBUSH WE, WILD MD, MAGUIRE EH.Expression of the platelet-activating factor receptor in human spermatozoa:differences in messenger ribonucleic acid content and protein distribution between normal and abnormal spermatozoa[J].Fertil Steril, 2000, 73 (5) :967-971.

[11]ZHAO YF, ZHAI WL, ZHANG SJ, et al.Protection effect of triptolide to liver injury in rats with severe acute pancreatitis[J].Hepatobiliary Pancreat Dis Int, 2005, 4 (4) :604-608.

[12]POORAN N, INDARAM A, SINGH P, et al.Cytokines (IL-6, IL-8, TNF) :early and reliable predictors of severe acute pancreatitis[J].J Clin Gastroenterol, 2003, 37 (3) :263-266.

[13]KIHARA Y, YOSHIKAWA H, HONDA H, et al.Natural disruption of group 2 phospholipase A2 gene protects against choline-deficient ethionine-supplemented diet-induced acute pancreatitis and lung injury[J].Pancreas, 2005, 31 (1) :48-53.

[14]DIMAGNO MJ, WILLIAMS JA, HAO Y, et al.Endothelial nitric oxide synthase is protective in the initiation of caerulein-induced acute pancreatitis in mice[J].Am J Physiol Gastrointest Liver Physiol, 2004, 287 (1) :g80-g87.

[15]ARMSTRONG JA, CASH N, SOARES PM, et al.Oxidative stress in acute pancreatitis:lost in translation?[J].Free Radic Res, 2013, 47 (11) :917-933.

[16]GERASIMENKO JV, GERASIMENKO OV, PETERSEN OH.The role of Ca2+in the pathophysiology of pancreatitis[J].J Physiol, 2014, 592 (Pt 2) :269-280.

[17]ZAHEER A, SINGH VK, QURESHI RO, et al.The revised Atlanta classification for acute pancreatitis:updates in imaging terminology and guidelines[J].Abdom Imaging, 2013, 38 (1) :125-136.

[18]LENG F, YANG L, CHANG ZG, et al.Classification for acute pancreatitis-2012:revision of the Atlanta classification and definitions by international consensus[J].J Clin Hepatol, 2013, 29 (4) :Ⅰ-Ⅶ. (in Chinese) 冷芳, 杨力, 常志刚, 等.急性胰腺炎分类——2012:亚特兰大分类和定义修订的国际共识[J].临床肝胆病杂志, 2013, 29 (4) :Ⅰ-Ⅶ.

[19]KOKSOY FN, YANKOL Y, SEN OE, et al.Preventive effects of enoxaparin and hesperidin in cerulein-induced acute pancreatitis in rats[J].Turk J Gastroenterol, 2013, 24 (6) :495-501.

[20]LI S, CHEN X, WU T, et al.Role of heparin on serum VEGF levels and local VEGF contents in reducing the severity of experimental severe acute pancreatitis in rats[J].Scand J Gastroenterol, 2012, 47 (2) :237-244.

[21]QIU F, LU XS, HUANG YK.Protective effect of low-molecularweight heparin on pancreatic encephalopathy in severe acute pancreatic rats[J].Inflamm Res, 2012, 61 (11) :1203-1209.

[22]UHLMANN D, LAUER H, SERR F, et al.Pathophysiological role of platelets in acute experimental pancreatitis:influence of endothelin A receptor blockade[J].Cell Tissue Res, 2007, 327 (3) :485-492.

[23]MARTIGNONI ME, CEYHAN GO, AYUNI E, et al.Endothelin receptor antagonists are not beneficial in the therapy of acute experimental pancreatitis[J].Langenbecks Arch Surg, 2004, 389 (3) :184-192.

[24]MANN O, TIEFENBACHER WJ, KAIFI J, et al.Effect of plateletactivating factor antagonist WEB 2086 on microcirculatory disorders in acute experimental pancreatitis of graded severity[J].Pancreas, 2009, 38 (1) :58-64.

[25]HIRANO T, HIRANO K.Thromboxane A2 receptor antagonist prevents pancreatic microvascular leakage in rats with caerulein-induced acute pancreatitis[J].Int J Surg Investig, 1999, 1 (3) :203-210.

[26]DOBOSZ M, HAC S, MIONSKOWSKA L, et al.Organ microcirculatory disturbances in experimental acute pancreatitis.A role of nitric oxide[J].Physiol Res, 2005, 54 (4) :363-368.

[27]LEINDLER L, MORSCHL E, LASZLO F, et al.Importance of cytokines, nitric oxide, and apoptosis in the pathological process of necrotizing pancreatitis in rats[J].Pancreas, 2004, 29 (2) :157-161.

[28]BLOECHLE C, KUSTERER K, KUEHN RM, et al.Inhibition of bradykinin B2 receptor preserves microcirculation in experimental pancreatitis in rats[J].Am J Physiol, 1998, 274 (1 Pt 1) :g42-g51.

[29]GRIESBACHER T, RAINER I, TIRAN B, et al.Kallikrein inhibitors limit kinin B (2) antagonist-induced progression of oedematous to haemorrhagic pancreatitis in rats[J].Br J Pharmacol, 2008, 155 (6) :865-874.

[30]KECK T, WERNER J, BANAFSCHE R, et al.Oxygen radicals promote ICAM-1 expression and microcirculatory disturbances in experimental acute pancreatitis[J].Pancreatology, 2003, 3 (2) :156-163.

[31]ITO Y, LUGEA A, PANDOL SJ, et al.Substance P mediates cerulein-induced pancreatic microcirculatory dysfunction in mice[J].Pancreas, 2007, 34 (1) :138-143.

[32]ZHANG XP, SHI Y, ZHANG L.Progress in the study of therapeutic effects of traditional Chinese medicine and extracts in treating severe acute pancreatitis[J].JOP, 2007, 8 (6) :704-714.

[33]CAI Z, KNORR D, SMETANSKA I.Enhanced anthocyanins and resveratrol production in Vitis vinifera cell suspension culture by indanoyl-isoleucine, N-linolenoyl-L-glutamine and insect saliva[J].Enzyme Microb Technol, 2012, 50 (1) :29-34.

[34]PIOTROWSKA H, KUCINSKA M, MURIAS M.Biological activity of piceatannol:leaving the shadow of resveratrol[J].Mutat Res, 2012, 750 (1) :60-82.

[35]KARALIS F, SOUBASI V, GEORGIOU T, et al.Resveratrol ameliorates hypoxia/ischemia-induced behavioral deficits and brain injury in the neonatal rat brain[J].Brain Res, 2011, 1425:98-110.

[36]SHA H, MA Q, JHA RK, et al.Resveratrol suppresses microcirculatory disturbance in a rat model of severe acute pancreatitis[J].Cell Biochem Biophys, 2013, 67 (3) :1059-1065.

[37]ANDERSSON E, AXELSSON J, PEDERSEN LC, et al.Treatment with anti-factor VIIa in acute pancreatitis in rats:blocking both coagulation and inflammation?[J].Scand J Gastroenterol, 2007, 42 (6) :765-770.

[38]DU BQ, YANG YM, CHEN YH, et al.N-acetylcysteine improves pancreatic microcirculation and alleviates the severity of acute necrotizing pancreatitis[J].Gut Liver, 2013, 7 (3) :357-362.

[39]NIKFARJAM M, CUTHBERTSON CM, MALCONTENTI-WILSON C, et al.Hyperbaric oxygen therapy reduces severity and improves survival in severe acute pancreatitis[J].J Gastrointest Surg, 2007, 11 (8) :1008-1015.

[40]ONUR E, PAKSOY M, BACA B, et al.Hyperbaric oxygen and Nacetylcysteine treatment in L-arginine-induced acute pancreatitis in rats[J].J Invest Surg, 2012, 5 (1) :20-28.

Relative Articles

[1]	Di WU, Dahua DAI, Wenmei LIANG, Bao FU, Xiaoyun FU. Clinical features of acute pancreatitis in pregnancy and related risk factors[J]. Journal of Clinical Hepatology, 2024, 40(5): 1009-1015. doi: 10.12449/JCH240522
[2]	Yufeng ZHENG, Xulei ZHANG, Yuhang WENG, Yongfeng YANG. Etiological spectrum and clinical features of patients with unexplained liver disease manifesting as isolated jaundice: An analysis of 91 cases[J]. Journal of Clinical Hepatology, 2023, 39(5): 1105-1109. doi: 10.3969/j.issn.1001-5256.2023.05.016
[3]	Chengsi ZHAO, Weijie YAO, Peng YUAN, Zuozheng WANG. Time distribution of risk factors for secondary pancreatic infection in acute pancreatitis[J]. Journal of Clinical Hepatology, 2022, 38(7): 1686-1690. doi: 10.3969/j.issn.1001-5256.2022.07.044
[4]	Ruihua ZHANG, Tingting QIN, Yueming SHAO, Yu ZHANG, Yang WANG, Xiaoyu WEN. Jaundice and portal hypertension caused by hepatic epithelioid hemangioendothelioma: A case report[J]. Journal of Clinical Hepatology, 2021, 37(7): 1662-1664. doi: 10.3969/j.issn.1001-5256.2021.07.036
[5]	Si XIE, Ming YANG, Yuan HUANG, Lai WEI. Differential diagnosis and treatment of jaundice after comprehensive treatment of advanced primary liver cancer: A case report[J]. Journal of Clinical Hepatology, 2021, 37(2): 400-402. doi: 10.3969/j.issn.1001-5256.2021.02.030
[6]	Wang CaiBin, Su Yang. Risk factors for posthepatectomy liver failure and related prevention and treatment methods[J]. Journal of Clinical Hepatology, 2020, 36(9): 2119-2124. doi: 10.3969/j.issn.1001-5256.2020.09.048
[7]	Cao Yuan, Yao GuoXiang, Shi YiHai. An excerpt of international consensus guidelines for risk factors in chronic pancreatitis (2020)[J]. Journal of Clinical Hepatology, 2020, 36(8): 1720-1722. doi: 10.3969/j.issn.1001-5256.2020.08.008
[8]	Lei Yu, Li JiaJia, Liu RongAn, Ceng Fan, Li GuiSen, Lan YunPing. Clinical features of patients with sepsis-induced cholestatic jaundice and risk factors for death[J]. Journal of Clinical Hepatology, 2020, 36(5): 1065-1071. doi: 10.3969/j.issn.1001-5256.2020.05.023
[9]	Yao ChengZi, Feng Gong, Yu WenSi, Du Huan, Mi Man. Risk factors for the development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(2): 433-436. doi: 10.3969/j.issn.1001-5256.2020.02.044
[10]	Ren DanDan, Liu Na, Zhou LuLu, Zhang Nan, Li ChunXia, Dong Bing, Xu GuangHua. Risk factors for hepatitis B virus-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(7): 1634-1638. doi: 10.3969/j.issn.1001-5256.2020.07.041
[11]	Luo XiaoKe, Li XiaoLing, Yang LiMing, Wang XiaoHong. Efficacy of magnesium isoglycyrrhizinate in treatment of hepatitis E with severe jaundice[J]. Journal of Clinical Hepatology, 2014, 30(6): 537-539. doi: 10.3969/j.issn.1001-5256.2014.06.014
[12]	Yu Zheng, Jia JiDong. Risk factors, diagnostic criteria, and drug discontinuation criteria for drug- induced liver injury[J]. Journal of Clinical Hepatology, 2013, 29(9): 674-677. doi: 10.3969/j.issn.1001-5256.2013.09.010
[13]	Bao XuLi, Tian Zhou, Chen QingFeng, Li Li, Zhang Lei, Lu: Jun. One case of primary hepatic amyloidosis characterized by jaundice[J]. Journal of Clinical Hepatology, 2013, 29(12): 943-944. doi: 10.3969/j.issn.1001-5256.2013.12.018
[14]	Wu XiaoQing, Wan Hong. Causes of liver failure and impact analysis of prognostic risk factors[J]. Journal of Clinical Hepatology, 2013, 29(4): 294-296+304.
[15]	Chen Qian, Wen XiaoYu, Pan Yu. Jaundice due to hepatic syphilis: A case report[J]. Journal of Clinical Hepatology, 2013, 29(4): 303-304.
[16]	Yang ZongGuo, Chen XiaoRong, Lu YunFei, Liu Cheng. Decotion in chronic hepatitis B patients (damp-heat blood stasis syndrome) with low-grade jaundice[J]. Journal of Clinical Hepatology, 2012, 28(10): 771-774+784.
[17]	Shi HaiDong. Clinical observation of alprostadil injection in the treatment of liver cirrhosis with jaundice[J]. Journal of Clinical Hepatology, 2011, 27(9): 962-964.
[18]	Dou WeiJia, Zhou Lin, Wu KaiChun. Risk factors of chronic pancreatitis[J]. Journal of Clinical Hepatology, 2011, 27(11): 1180-1183.
[19]	Wang Hong, Wang YingMin, Zhang Bo. Prospective analysis of risk factors for the occurrence of hepatocellular carcinoma in patients with post-hepatitis B cirrhosis[J]. Journal of Clinical Hepatology, 2007, 23(1): 34-35.
[20]	Wang Hong. Risk factors for patients with cirrhosis developed renal dysfunction[J]. Journal of Clinical Hepatology, 2004, 20(2): 101-102.

Supplements(0)

Cited By

Cited by

Periodical cited type(3)

1.	程玉鑫，刘亮，董适毓，李胜超，张萌. 外泌体蛋白、mRNA及非编码RNA调节肝癌发生和发展的研究进展. 实用医学杂志. 2024(06): 748-755 .
2.	王玲，曹信宇，商伟芳，丁秀婷. 慢性乙型肝炎患者外泌体miR-335-5p与肝硬化严重程度的相关性. 中国热带医学. 2024(03): 326-332 .
3.	窦金萍，高维崧，韦双，高新桃，李轶女. 外泌体MicroRNA在抗病毒免疫中的功能分析. 生物技术通报. 2024(05): 48-57 .

Other cited types(3)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (3035) PDF downloads(600)

Pathogenetic mechanism of microcirculatory disturbance and treatment advances in acute pancreatitis

DOI: 10.3969/j.issn.1001-5256.2014.08.033